BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to SKBR3 cell line is 111
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| POU5F1 | 9221 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting and IF staining | NA | 0.52 | 0.6448 | 29100426 |
| POU5F1 | 9221 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting and IF staining | NA | 0.52 | 0.6448 | 29100426 |
| POU5F1 | 9221 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.6448 | 18083101 |
| POU5F1 | 9221 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 35326667 |
| POU5F1 | 9221 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | qRT-PCR followed by SP assay and SFA | NA | 0.52 | 0.6448 | 30613295 |
| POU5F1 | 9221 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | qRT-PCR followed by SP assay and SFA | NA | 0.52 | 0.6448 | 30613295 |
| POU5F1 | 9221 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Epirubicin | SFA followed by qRT-PCR | NA | 0.52 | 0.6448 | 18083101 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR and Western Blotting | NA | 0.48 | 0.684 | 30541574 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR and Western Blotting | NA | 0.48 | 0.684 | 30541574 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR followed by Western Blotting | NA | 0.48 | 0.684 | 31545416 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR followed by Western Blotting | NA | 0.48 | 0.684 | 31545416 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by ALDEFLUOR assay and FACs | NA | 0.48 | 0.684 | 31726667 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 33389402 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 35220209 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by ALDEFLUOR assay | NA | 0.48 | 0.684 | 32859993 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 19190339 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 19190339 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 29080749 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 29080749 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 29620216 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay followed by SFA | NA | 0.48 | 0.684 | 29620216 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay followed by SP assay and SFA | NA | 0.48 | 0.684 | 30613295 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | ALDEFLUOR assay followed by SP assay and SFA | NA | 0.48 | 0.684 | 30613295 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Fructose | SFA followed by ALDEFLUOR assay | NA | 0.48 | 0.684 | 29796188 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Fructose | SFA followed by ALDEFLUOR assay | NA | 0.48 | 0.684 | 29796188 |
| ALDH1A1 | 402 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.48 | 0.684 | 31726667 |
| ALDH1A3 | 409 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR followed by Western Blotting | NA | 0.48 | 0.0201 | 31545416 |
| ALDH1A3 | 409 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR followed by Western Blotting | NA | 0.48 | 0.0201 | 31545416 |
| EPCAM | 11529 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR followed by Western Blotting | NA | 0.48 | 0.211 | 31545416 |
| EPCAM | 11529 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR followed by Western Blotting | NA | 0.48 | 0.211 | 31545416 |
| MIR655 | 32911 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR and IF staining followed by SFA and Migration Invasion assay | NA | 0.44 | 0.0011 | 29321644 |
| MIR655 | 32911 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | RT-PCR and IF staining followed by SFA and Migration Invasion assay | NA | 0.44 | 0.0011 | 29321644 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by Western Blotting | NA | 0.4 | 0.456 | 30620624 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by Western Blotting | NA | 0.4 | 0.456 | 30620624 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.456 | 29100426 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.456 | 29100426 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 0.456 | 31579408 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 0.456 | 31579408 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs | NA | 0.4 | 0.456 | 29080749 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs | NA | 0.4 | 0.456 | 29080749 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | 5-Fluorouracil | FACs | NA | 0.4 | 0.456 | 29371950 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | 5-Fluorouracil | FACs | NA | 0.4 | 0.456 | 29371950 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs | NA | 0.4 | 0.456 | 31729259 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 31599500 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 31599500 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 31695436 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 31695436 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Epirubicin | SFA followed by FACs and SP assay | NA | 0.4 | 0.456 | 18083101 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 18083101 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | TGF-Beta | SFA followed by FACs | NA | 0.4 | 0.456 | 28702892 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Fructose | SFA followed by FACs | NA | 0.4 | 0.456 | 29796188 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Fructose | SFA followed by FACs | NA | 0.4 | 0.456 | 29796188 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 31579408 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 31579408 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 31726667 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 31726667 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by Western Blotting | NA | 0.4 | 1 | 30620624 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by Western Blotting | NA | 0.4 | 1 | 30620624 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 1 | 29100426 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs and Western Blotting | NA | 0.4 | 1 | 29100426 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 1 | 31579408 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 1 | 31579408 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 1 | 35205696 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs | NA | 0.4 | 1 | 29080749 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs | NA | 0.4 | 1 | 29080749 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | 5-Fluorouracil | FACs | NA | 0.4 | 1 | 29371950 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | 5-Fluorouracil | FACs | NA | 0.4 | 1 | 29371950 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs | NA | 0.4 | 1 | 31729259 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 1 | 31599500 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 1 | 31599500 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 1 | 31695436 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.4 | 1 | 31695436 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SP assay and SFA | NA | 0.4 | 1 | 30613295 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SP assay and SFA | NA | 0.4 | 1 | 30613295 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Epirubicin | SFA followed by FACs and SP assay | NA | 0.4 | 1 | 18083101 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 1 | 18083101 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | TGF-Beta | SFA followed by FACs | NA | 0.4 | 1 | 28702892 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Fructose | SFA followed by FACs | NA | 0.4 | 1 | 29796188 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Fructose | SFA followed by FACs | NA | 0.4 | 1 | 29796188 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 1 | 31579408 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 1 | 31579408 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 1 | 31726667 |
| CD44 | 1681 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by FACs | NA | 0.4 | 1 | 31726667 |
| CTAG1B | 2491 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IF staining and SFA | NA | 0.36 | 0.0011 | 31579408 |
| CTAG1B | 2491 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IF staining and SFA | NA | 0.36 | 0.0011 | 31579408 |
| CTAG1B | 2491 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IHC staining and SFA | NA | 0.36 | 0.0011 | 31579408 |
| CTAG1B | 2491 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by IHC staining and SFA | NA | 0.36 | 0.0011 | 31579408 |
| ABCG2 | 74 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1739 | 18083101 |
| CTNNB1 | 2514 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 29100426 |
| CTNNB1 | 2514 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 29100426 |
| NANOG | 20857 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.5461 | 30620624 |
| NANOG | 20857 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.5461 | 30620624 |
| NANOG | 20857 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.5461 | 35326667 |
| NANOG | 20857 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | qRT-PCR followed by SP assay and SFA | NA | 0.28 | 0.5461 | 30613295 |
| NANOG | 20857 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | qRT-PCR followed by SP assay and SFA | NA | 0.28 | 0.5461 | 30613295 |
| NOTCH2 | 7882 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 29100426 |
| NOTCH2 | 7882 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 29100426 |
| PROM1 | 9454 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.7582 | 30620624 |
| PROM1 | 9454 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.7582 | 30620624 |
| SOX2 | 11195 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.5695 | 29100426 |
| SOX2 | 11195 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.5695 | 29100426 |
| SOX2 | 11195 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.5695 | 35326667 |
| SOX2 | 11195 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | qRT-PCR followed by SP assay and SFA | NA | 0.28 | 0.5695 | 30613295 |
| SOX2 | 11195 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | qRT-PCR followed by SP assay and SFA | NA | 0.28 | 0.5695 | 30613295 |
| STAT3 | 11364 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0223 | 31619923 |
| STAT3 | 11364 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0223 | 31619923 |
| TENM4 | 29945 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 33672732 |
| C5 | 1331 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs for CSC marker followed by IF staining | NA | 0.24 | 0.0021 | 35220209 |
| MYC | 7553 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1304 | 35326667 |
| CD24 | 1645 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | NA | FACs followed by SFA | NA | 0.12 | 0.456 | 35205696 |
| LIN28A | 15986 | LTM | HER2 Positive Breast Cancer | Adenocarcinoma | SKBR3 | Epirubicin | SFA followed by FACs and SP assay | NA | 0.12 | 0.0138 | 18083101 |